ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO684

Glucose Metabolic Profiles in Renal Tissue of an Orthologous PCK Rat Model of Human PKD Using Metabolic and Proteomic Analyses

Session Information

Category: Genetic Diseases of the Kidney

  • 1001 Genetic Diseases of the Kidney: Cystic


  • Nagao, Shizuko, Fujita Health University, Toyoake, Aichi, Japan
  • Kugita, Masanori, Fujita Health University, Toyoake, Aichi, Japan
  • Kumamoto, Kanako, Fujita Health University, Toyoake, Aichi, Japan
  • Yoshimura, Aya, Fujita Health University, Toyoake, Aichi, Japan
  • Yamaguchi, Tamio, Suzuka University of Medical Science, Suzuka, Mie, Japan
  • Nakajima, Kazuki, Fujita Health University, Toyoake, Japan
  • Takahashi, Kazuo, Fujita Health University School of Medicine, Toyoake, AICHI-KEN, Japan
  • Yuzawa, Yukio, Fujita Health University School of Medicine, Toyoake, AICHI-KEN, Japan

Polycystic kidney disease (PKD) is an inherited disorder characterized by excessive cellular proliferation and fluid secretion of the tubular epithelial cells due to genetic mutation. To detect altered renal metabolic and enzymatic activities, we performed metabolic and proteomic analyses in the PCK rat, an orthologous model of human autosomal recessive PKD.


In renal tissue of 20-week-old PCK and age-matched normal rats, metabolic products were analyzed by using capillary electrophoresis time-of-flight mass spectrometry and MasterHands metabolome analysis software; proteomic products were analyzed using Orbitrap mass spectrometry and Proteome Discoverer™ software.


Metabolic analysis revealed a 1.8-fold increase in cAMP content in PCK cystic kidneys compared with normal kidneys, the same trend seen from our previous study using radioimmunoassay. Upstream glycolysis metabolites were decreased as follows: glucose 1-phosphate (0.5-fold), glucose 6-phosphate (0.5-fold) and fructose 6-phosphate (F6P, 0.6-fold); and downstream, 3-phosphoglyceric acid (3-PG, 4.2-fold) was increased in PCK samples. 2-Phosphoglyceric acid and phosphoenolpyruvate were detected in only PCK kidneys, not in normal kidneys. On proteomic analysis, increased fructose-bisphosphate aldolase A, an enzyme that converts F6P to 3-PG, was seen in PCK rats (3.6-fold). Tricarboxylic acid (TCA) cycle metabolites were increased as follows: citric acid (23-fold), cis-aconitic acid (8.5-fold), isocitric acid (32-fold), succinic acid (1.6-fold), fumaric acid (1.7-fold), and malic acid (2.1-fold) in PCK kidneys; 2-oxoglutarate was detected in only PCK kidneys. Citrate synthase, which converts acetyl CoA (2.0-fold) to citric acid, was increased (7.5-fold) in PCK kidneys. In the non-oxidative phase of the pentose phosphate pathway, increased ribose 5-phosphate (R5P) was detected in only PCK kidneys. Increased transaldolase (3.0-fold), which converts sedoheptulose 7-phosphate (S7P, 0.6-fold) to F6P, was found in PCK kidneys. Also, transketolase (2.4-fold), which converts S7P to R5P, was increased in PCK cystic kidneys.


These findings suggest that increased activity of pentose phosphate pathway as well as glycolysis and TCA cycle may play important roles in promoting PKD progression.


  • Government Support - Non-U.S.